Literature DB >> 27861746

Effect of hospital volume on processes of breast cancer care: A National Cancer Data Base study.

Tina W F Yen1,2, Liliana E Pezzin2,3, Jianing Li2,4, Rodney Sparapani2,4, Purushuttom W Laud2,4, Ann B Nattinger2,3.   

Abstract

BACKGROUND: The purpose of this study was to examine variations in delivery of several breast cancer processes of care that are correlated with lower mortality and disease recurrence, and to determine the extent to which hospital volume explains this variation.
METHODS: Women who were diagnosed with stage I-III unilateral breast cancer between 2007 and 2011 were identified within the National Cancer Data Base. Multiple logistic regression models were developed to determine whether hospital volume was independently associated with each of 10 individual process of care measures addressing diagnosis and treatment, and 2 composite measures assessing appropriateness of systemic treatment (chemotherapy and hormonal therapy) and locoregional treatment (margin status and radiation therapy).
RESULTS: Among 573,571 women treated at 1755 different hospitals, 38%, 51%, and 10% were treated at high-, medium-, and low-volume hospitals, respectively. On multivariate analysis controlling for patient sociodemographic characteristics, treatment year and geographic location, hospital volume was a significant predictor for cancer diagnosis by initial biopsy (medium volume: odds ratio [OR] = 1.15, 95% confidence interval [CI] = 1.05-1.25; high volume: OR = 1.30, 95% CI = 1.14-1.49), negative surgical margins (medium volume: OR = 1.15, 95% CI = 1.06-1.24; high volume: OR = 1.28, 95% CI = 1.13-1.44), and appropriate locoregional treatment (medium volume: OR = 1.12, 95% CI = 1.07-1.17; high volume: OR = 1.16, 95% CI = 1.09-1.24).
CONCLUSIONS: Diagnosis of breast cancer before initial surgery, negative surgical margins and appropriate use of radiation therapy may partially explain the volume-survival relationship. Dissemination of these processes of care to a broader group of hospitals could potentially improve the overall quality of care and outcomes of breast cancer survivors. Cancer 2017;123:957-66.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  National Cancer Data Base; breast cancer; chemotherapy; hormonal therapy; hospital volume; processes of care; radiation therapy; surgical margins

Mesh:

Year:  2016        PMID: 27861746     DOI: 10.1002/cncr.30413

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer.

Authors:  Tina W F Yen; Zhuping Garacci; Purushottam W Laud; Liliana E Pezzin; Ann B Nattinger
Journal:  Breast Cancer       Date:  2021-01-04       Impact factor: 4.239

2.  Initiating Low-Value Inhaled Corticosteroids in an Inception Cohort with Chronic Obstructive Pulmonary Disease.

Authors:  Laura J Spece; Lucas M Donovan; Matthew F Griffith; Thomas Keller; Laura C Feemster; Nicholas L Smith; David H Au
Journal:  Ann Am Thorac Soc       Date:  2020-05

3.  Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.

Authors:  Ronnie Zipkin; Andrew Schaefer; Mary Chamberlin; Tracy Onega; Alistair J O'Malley; Erika L Moen
Journal:  Cancer Med       Date:  2021-01-16       Impact factor: 4.452

4.  Latent composite indicators for evaluating adherence to guidelines in patients with a colorectal cancer diagnosis.

Authors:  Rossella Murtas; Adriano Decarli; Maria Teresa Greco; Anita Andreano; Antonio Giampiero Russo
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

5.  Can Regionalization of Care Reduce Socioeconomic Disparities in Breast Cancer Survival?

Authors:  Ann B Nattinger; Nicole Rademacher; Emily L McGinley; Nina A Bickell; Liliana E Pezzin
Journal:  Med Care       Date:  2021-01       Impact factor: 3.178

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.